Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Eman El-Khateeb"'
Autor:
Ammena Y. Binsaleh, Mostafa M. Bahaa, Thanaa A. Elmasry, Eman I. Elberri, Fedaa A. Kotkata, Eman El-Khateeb, Marwa Kamal, Marwa Ahmed El-samongy, Amir O. Hamouda, Amira M. Alghamdi, Sarah Alrubia, Muhammed M. Salahuddin, Nashwa Eltantawy
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
IntroductionAtopic dermatitis (AD) is a type of chronic inflammatory disorder that affects children.AimTo investigate whether hydrocortisone or tacrolimus could be more effective for treating AD in children.Patients and methodsThis clinical randomize
Externí odkaz:
https://doaj.org/article/896af68b27cd4214b5fff2aeca427fcc
Autor:
Eman El-Khateeb, Eman I. El-Berri, Esraa M. Mosalam, Mohamed Z. Nooh, Shimaa Abdelsattar, Amira M. Alghamdi, Sarah Alrubia, Mahmoud S. Abdallah
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Type 2 diabetes mellitus (T2DM) is common with obesity. Metformin is a first-line therapy for this condition. However, it has only a minor impact on weight loss in some patients.Aim: This study aimed to evaluate the effectiveness, tolerab
Externí odkaz:
https://doaj.org/article/ab8fabb54ec5483a9b9a4781012c558d
Autor:
Eman El-Khateeb PhD, Sahar Mohamed El-Haggar PhD, Osama El-Razaky MD, Mohamed Ramadan El-Shanshory MD, Tarek Mohamed Mostafa PhD
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics, Vol 27 (2022)
Background: Pulmonary hypertension (PHT) is common in β-thalassemia patients due to hemolysis, iron overload and diminished nitric oxide (NO) levels. Biochemical markers can help to understand the pathophysiology and to introduce new therapies for t
Externí odkaz:
https://doaj.org/article/4700590eea4f44beb9492915b38fae4c
Publikováno v:
PPAR Research, Vol 2013 (2013)
Background. Activation of PPARα modulates cholesterol metabolism and suppresses bile acid synthesis. This study aims to evaluate the effect of PPARα agonists, fenofibrate, bezafibrate, and gemfibrozil, on acute cholestasis induced by ethinylestradi
Externí odkaz:
https://doaj.org/article/a56f26724f0246669737ff414c4657e9
Publikováno v:
Alimentary Pharmacology & Therapeutics. 54:388-401
Background Prescription information for many drugs entering the market lacks dosage guidance for hepatic impairment. Dedicated studies for assessing the fate of drugs in hepatic impairment commonly stratify patients using Child-Pugh score. Child-Pugh
Autor:
Rohitash Jamwal, Eman El-Khateeb, Stephanie Malone, Aarzoo Thakur, Tsubasa Kameyama, Shakti Nagpal, Zhiyuan Tan, Chukwunonso K Nwabufo
Publikováno v:
Drug Metabolism Reviews. 53:434-458
A reliable, rapid, and effective bioanalytical method is essential for the determination of the pharmacokinetic, pharmacodynamic, and toxicokinetic parameters that inform the safety and efficacy profile of investigational drugs. The overall goal of b
Autor:
Eman El-Khateeb, Heeseung Jo, Shringi Sharma, Amin Rastomi-Hodjegan, Masoud Jamei, Venkatesh Pilla Reddy, Emily Lythgoe, Weifeng Tang, Natalie Giovino
Publikováno v:
British Journal of Clinical Pharmacology
Reddy, V P, El-Khateeb, E, Jo, H, Giovino, N, Lythgoe, E, Sharma, S, Tang, W, Jamei, M & Rastomi-Hodjegan, A 2020, ' Pharmacokinetics under the COVID-19 Storm ', British Journal of Clinical Pharmacology . https://doi.org/10.1111/bcp.14668
Reddy, V P, El-Khateeb, E, Jo, H, Giovino, N, Lythgoe, E, Sharma, S, Tang, W, Jamei, M & Rastomi-Hodjegan, A 2020, ' Pharmacokinetics under the COVID-19 Storm ', British Journal of Clinical Pharmacology . https://doi.org/10.1111/bcp.14668
Aims The storm-like nature of the health crises caused by COVID-19 has led to unconventional clinical trial practices such as the relaxation of exclusion criteria. The question remains: how can we conduct diverse trials without exposing subgroups of
Autor:
Zubida M. Al-Majdoub, Noura Alohali, Sibylle Neuhoff, Amin Rostami-Hodjegan, Eman El-Khateeb, Areti-Maria Vasilogianni, Narciso Couto, Lutz Schmitt, Yasmine Elmorsi, Daniel Scotcher, Sarah Alrubia, Jill Barber, Martyn Howard, Brahim Achour
Publikováno v:
Febs Letters
Al-Majdoub, Z, Achour, B, Couto, N, Howard, M, Elmorsi, Y, Scotcher, D, Alrubia, S, Elkhateeb, E, Vasilogianni, A M, Alohali, N, Neuhoff, S, Schmidt, L, Rostami-Hodjegan, A & Barber, J 2020, ' Mass Spectrometry-Based Abundance Atlas of ABC Transporters in Human Liver, Gut, Kidney, Brain, and Skin ', FEBS Letters . https://doi.org/10.1002/1873-3468.13982
Al-Majdoub, Z, Achour, B, Couto, N, Howard, M, Elmorsi, Y, Scotcher, D, Alrubia, S, Elkhateeb, E, Vasilogianni, A M, Alohali, N, Neuhoff, S, Schmidt, L, Rostami-Hodjegan, A & Barber, J 2020, ' Mass Spectrometry-Based Abundance Atlas of ABC Transporters in Human Liver, Gut, Kidney, Brain, and Skin ', FEBS Letters . https://doi.org/10.1002/1873-3468.13982
ABC transporters (ATP-binding cassette transporter) traffic drugs and their metabolites across membranes, making ABC transporter expression levels a key factor regulating local drug concentrations in different tissues and individuals. Yet, quantifica
Publikováno v:
El-Khateeb, E, Al-Majdoub, Z M, Rostami-Hodjegan, A, Barber, J & Achour, B 2021, ' Proteomic Quantification of Changes in Abundance of Drug-Metabolizing Enzymes and Drug Transporters in Human Liver Cirrhosis: Different Methods, Similar Outcomes ', Drug Metabolism and Disposition, vol. 49, no. 8, DMD-AR-2021-000484, pp. 610-618 . https://doi.org/10.1124/dmd.121.000484
Model-based assessment of the effects of liver disease on drug pharmacokinetics requires quantification of changes in enzymes and transporters responsible for drug metabolism and disposition. Different proteomic methods are currently used for protein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52b88e86eba459400f6e0b55915702ec
https://doi.org/10.1124/dmd.121.000484
https://doi.org/10.1124/dmd.121.000484
Autor:
Areti-Maria Vasilogianni, Eman El-Khateeb, Zubida M. Al-Majdoub, Sarah Alrubia, Amin Rostami-Hodjegan, Jill Barber, Brahim Achour
Publikováno v:
Vasilogianni, A M 2022, ' Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease ', Journal of Proteomics, vol. 263, 104601 . https://doi.org/10.1016/j.jprot.2022.104601
Model-based assessment of drug pharmacokinetics in liver disease requires quantification of abundance and disease-related changes in hepatic enzymes and transporters. This study aimed to assess performance of three label-free methods [high N (HiN), i